Latest News Entry
Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial
Company Completes Large Multi-Center, Randomized, Controlled Study of Novel Digital Medicine and Plans Regulatory Filing 2016/07/20
Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million
BOSTON--(BUSINESS WIRE)-- Akili Interactive Labs, Inc. ("Akili"), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. *Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products. With the M Ventures and Amgen Ventures investments, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals.
all portfolio news